Day One
Wednesday, February 19, 2025
7:30 am Registration & Light Breakfast
8:20 am Chair’s Opening Remarks
Transforming Molecular Insights into Actionable Tools to Enable Real Time Monitoring of Patients & Drive Precision Oncology
8:30 am Harnessing Molecular Insights to Develop Clinically Actionable Tools for Transforming Patient Care
Synopsis
- How ctDNA and MRD are being applied in real-world clinical settings to guide personalized treatment decisions
- Evaluating the translation of molecular data into actionable tools that can streamline diagnosis, treatment, and monitoring
- How can we integrate molecular insights into routine clinical workflows to improve patient outcomes?
9:00 am Session Reserved for Foundation Medicine
9:30 am Integrating Liquid Biopsies into Clinical Workflows to Enhance Decision Making in Clinical Trials
Synopsis
- Leveraging ctDNA to provide continuous insights into micro-tumor environments
- Accurately validating the clinical utility of liquid biopsy tests to improve decision making
- Enhancing drug-development pipelines with real-time patient monitoring for improved patient treatment and personalized therapy adjustments
10:00 am Session Reserved for Guardant Health
10:30 am Morning Break & Speed Networking
Synopsis
As the Clinical Biomarkers and Liquid Biopsy community unite once more, this valuable session will ensure that you can connect with your peers in the room to make new and lasting connections. All attendees will have the opportunity to meet and network with their industry peers.
Defining Robust Clinical Endpoints with MRD to Enhance Long-Term Survival Prediction & Optimize Patient Outcomes
11:30 am Pioneering Liquid Biopsies with MRD in Oncology for Accelerated Approval in Multiple Myeloma
Synopsis
- Understanding the significance of MRD as a key treatment response indicator in multiple myeloma
- Demonstrating the evidence of MRD negativity predicting long-term survival
- Pioneering novel approvals for MRD as clinical endpoints
12:00 pm Session Reserved for Caris Life Sciences
12:30 pm DEI Panel: Forging Pathways to Equitable Precision Medicine by Ensuring Universal Access to Liquid Biopsies & MRD Detection
Synopsis
- Discussing how liquid biopsies can reduce disparities in early cancer detection and monitoring, improving outcomes for underserved and underrepresented communities globally
- Evaluating how current strategies are working to ensure equal access to liquid biopsies and MRD detection, regardless of socioeconomic status
- Analysing the impact of MRD as an objective measure, irrespective of gender or ethnicity, to affordably diagnose patients
1:30 pm Networking Lunch
Track A: Discovery & Technology Innovation
Enhancing Predictive Biomarkers through Multi-Omics & Advanced MRD Detection for Refined Patient Selection Strategies
2:30 pm Building Robust Bioinformatics Pipelines for Liquid Biopsy Data to Enhance Precision Outcomes
Synopsis
- Demonstrating methods to normalize heterogeneous liquid biopsy data from various providers to achieve consistent analysis
- Leveraging machine learning to enhance liquid biopsy data accuracy, aligning closer to tissue biopsy standards
3:00 pm ESR1 & Beyond: Leveraging Exosomes for Highly Sensitive LBx Solutions
Synopsis
- Exosomes enable more complete and sensitive disease detection than cfDNA alone with unparalleled sensitivity (<0.1%VAF) to detect ESR1Â mutations on widely available instruments.
- The QuantideX® qPCR ESR1 exoMutation Kit (RUO) combines co-enrichment of ctDNA and exosomal RNA, qPCR reagents, and automated push-button software for a complete LBx solution for clinical research laboratories everywhere.
3:30 pm Panel Discussion: Improving MRD Detection & Leveraging Multi-omics to Refine Predictive Biomarkers for Augmented Treatment Strategies
Synopsis
- Investigating how advanced MRD detection methods are being used to refine the identification of biomarkers of treatment response
- Exploring the impact of multi-omics on biomarker detection
- What sensitivity is sufficient to reliably identify predictive biomarkers?
- How to ensure regulatory guidelines are adhered to whilst leveraging novel technology
4:00 pm Session Reserved for Biofidelity
Track B: Clinical Development & Commercialization
Leveraging Liquid Biopsies to Optimize Clinical Trial Design for Better Dosage Regimes & Enhanced Patient Selection
2:30 pm Redefining Patient Selection Strategies with Liquid Biopsies to Revolutionize Patient Safety in Clinical Trials
Synopsis
- Harnessing ctDNA to provide novel biomarker insights for improved patient selection
- Integrating molecular insights into patient selection strategies
- Understanding the commercial advantages of improved patient selection
3:00 pm Session Reserved for Personalis
3:30 pm Panel Discussion: Harnessing MRD to Inform Clinical Trial Decision Making & Improve Dosage Regimes
Synopsis
- How to integrate MRD into clinical trial designs to tailor dosage regimes more precisely
- Leveraging MRD insights to refine dosage escalation and de-escalation protocols for optimal efficacy and safety
- How to use MRD data to adjust treatment strategies and inform Standard of Care protocols
4:00 pm Evaluation of Liquid Biopsy NGS Assay Kits to Improve Access to Rapid, Decentralized Biomarker Testing for NSCLC in Daily Practice
Synopsis
- Access to cost effective, easy to use, distributed NGS kits for liquid biopsy testing (LBx) are critical to helping support more rapid treatment decision making for cancer patients. These kit-based methods allow a broad range of laboratories to perform high-quality NGS testing, which improves patient access to targeted therapies in a short turnaround time
- Kitted LBx assays can typically be categorized into either amplicon-based targeted panels or hybrid capture based CGP assays, with varying costs, NGS workflows, including automation of different steps and resulting genomic content
- A summary of our evaluation on site of multiple NGS-based LBx products, review their features and benefits and discuss how they might be used clinically to help more effectively and rapidly genomically profile patients for a better care in advanced NSCLC
4:30 pm Afternoon Networking Break
Innovating Liquid Biopsy Strategies to Decode Tumor Complexity & Enhance Oncology Insights for Better Cancer Treatments
5:00 pm Uncovering the Role of Circulating Cancer Cell Clusters in Metastasis & Therapeutic Targeting: A Novel Approach in Liquid Biopsy
Synopsis
- Circulating metastatic cancer cell clusters (MCCs) provide one of the worst prognoses for cancer patients
- Routine and efficient capture of MCCs is essential for diagnostic, prognostic, and therapeutic approaches
- Anti-metastatic drugs targeting MCCs independent of treatment against primary tumours are going to bring significant benefit to survival and quality of life to nearly all cancer patients
5:30 pm Panel Discussion: Pre-Analytical Insights to Enhance Liquid Biopsy Development Success
Synopsis
- Ensure compliance with evolving global standards to future-proof your studies
- Optimize pre-analytical protocols to generate consistent, high-quality results that drive impactful discoveries
- Ensure your assays capture the right analytes with precision, leading to better clinical outcomes
6:00 pm Multi-Analytes Analysis in Prostate Cancer: Overcoming Tumor Heterogeneity Challenges with Liquid Biopsy
Synopsis
- Impact of tumor heterogeneity on drug development and patient selection
- Advantages of a multi-analyte biomarker approach in a phase 1 trial
- Opportunity, and challenges, of precision medicine for prostate cancer
6:30 pm Chair’s Closing Remarks
Streamlining Liquid Biopsy Operations & Advancing Biomarker Analysis to Promote Routine Use of Liquid Biopsies in Clinical Settings
5:00 pm Optimizing Clinical Biomarker Operations in Liquid Biopsy Trials: Streamlining Sample Collection to Analysis
Synopsis
- Ensuring sample integrity from collection to analysis to power reliable biomarker data
- Navigating patient timing, shipments, and lab workflows for streamlined trial operations
- Uncovering ctDNA profile shifts across dosing to drive impactful clinical outcomes
5:30 pm Roundtable Discussion: Integrating Liquid Biopsies into Clinical Guidelines to Enhance Routine Testing & Accelerate the Commercialization of Innovative Drug- Diagnostic Solutions
Synopsis
- Supporting the inclusion of Minimal Residual Disease (MRD) testing in clinical guidelines, ensuring widespread adoption and utilization in oncology practice
- Examining the types of evidence and research necessary to support the incorporation of liquid biopsies into established clinical guidelines
- Evaluating the implications of liquid biopsy inclusion in guidelines for pharmaceutical companies, diagnostic providers, and oncologists
6:00 pm Leveraging Liquid Biopsy as an Early Biomarker for Response & Dose Optimization in Early-Phase Oncology Trials
Synopsis
- Exploring the use of liquid biopsy as an early biomarker to guide dose optimization
- Providing insights into the application of liquid biopsy for realtime biomarker assessment, and predicting early response